Genetic Testing in Predicting Biomarkers of Recurrence in Patients With Prostate Cancer Undergoing Surgery

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

1,045

Participants

Timeline

Start Date

November 26, 2007

Primary Completion Date

July 13, 2016

Study Completion Date

July 8, 2026

Conditions
Prostate Cancer
Interventions
GENETIC

DNA analysis

Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery

GENETIC

DNA methylation analysis

Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery

GENETIC

RNA analysis

Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery

GENETIC

gene expression analysis

Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery

GENETIC

polymerase chain reaction

Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery

OTHER

diagnostic laboratory biomarker analysis

Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery

PROCEDURE

therapeutic conventional surgery

Trial Locations (1)

91010-3000

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT00977457 - Genetic Testing in Predicting Biomarkers of Recurrence in Patients With Prostate Cancer Undergoing Surgery | Biotech Hunter | Biotech Hunter